Abstract
Boston-based IFM Therapeutics has launched a new subsidiary called IFM Due to develop small-molecule drugs for autoimmune and inflammatory diseases. IFM previously developed activators of a protein called STING—stimulator of interferon genes—which it sold to Bristol-Myers Squibb as part of a 2017 deal worth $300 million. Activating STING is a promising strategy for boosting cancer immunotherapies. Now IFM Due plans to develop inhibitors of STING, which is overactive in some autoimmune diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
